分子对接研究和分子动力学模拟分析:确定糖原合成酶激酶-3β对阿尔茨海默病的新型atp竞争性抑制。

Q2 Pharmacology, Toxicology and Pharmaceutics
F1000Research Pub Date : 2025-05-27 eCollection Date: 2024-01-01 DOI:10.12688/f1000research.145391.3
Suggala Ramya Shri, Yogendra Nayak, Sreedhara Ranganath Pai
{"title":"分子对接研究和分子动力学模拟分析:确定糖原合成酶激酶-3β对阿尔茨海默病的新型atp竞争性抑制。","authors":"Suggala Ramya Shri, Yogendra Nayak, Sreedhara Ranganath Pai","doi":"10.12688/f1000research.145391.3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The discovery of an ideal and effective therapy is urgently required for the treatment of Alzheimer's disease (AD). The main pathological hallmarks of Alzheimer's disease that appear before the clinical symptoms are neurofibrillary tangles, amyloid plaques, brain inflammation, and neuronal atrophy throughout the cerebral cortex and hippocampus. GSK-3β (Glycogen Synthase Kinase-3β) is regarded as the most important and promising target for therapeutic use because GSK-3β expression levels increase with age and are the most abundant and hyperactive in the brains of patients with AD. GSK-3β activation or upregulation can contribute to neurodegeneration by promoting amyloid beta (Aβ) production and tau hyperphosphorylation. Whereas the underlying mechanism for abnormal production of GSK-3β in AD brains remains unclear.</p><p><strong>Methods: </strong>Maestro was used, which is Schrodinger, for our computational simulation studies. In the present work, different modules that were used in previous studies with a little modification, the modules such as Protein Preparation with the help of Protein Preparation Wizard, Ligand Preparation with the help of LigPrep, for ADME (Absorption, Distribution, Metabolism and Excretion) prediction Qikprop was used, for docking studies Glide module was used, Binding energy prediction the Prime was used and Molecular dynamic simulation (MDs) studies done using Desmond.</p><p><strong>Results: </strong>Our focus is mainly on an <i>in-silico</i> approach, focusing on library generation; first draw an IMID2 (imidazo [1,5-a]pyridine-3-carboxamide) scaffold structure at Enamine and subjected it to a substructure search to target the receptor grid region (ATP-competitive site) of 6Y9R. They were then subjected to various screening processes. Finally, nine compounds were subjected to MDs studies.</p><p><strong>Conclusions: </strong>Nine compounds showed good results with the most stable interactions. Among all the MD studies, the compound (Z3336252116) has shown good interaction and a good docking score. Further experiments and studies are required to confirm these results.</p>","PeriodicalId":12260,"journal":{"name":"F1000Research","volume":"13 ","pages":"773"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12121352/pdf/","citationCount":"0","resultStr":"{\"title\":\"Molecular docking studies and molecular dynamic simulation analysis: To identify novel ATP-competitive inhibition of Glycogen synthase kinase-3β for Alzheimer's disease.\",\"authors\":\"Suggala Ramya Shri, Yogendra Nayak, Sreedhara Ranganath Pai\",\"doi\":\"10.12688/f1000research.145391.3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The discovery of an ideal and effective therapy is urgently required for the treatment of Alzheimer's disease (AD). The main pathological hallmarks of Alzheimer's disease that appear before the clinical symptoms are neurofibrillary tangles, amyloid plaques, brain inflammation, and neuronal atrophy throughout the cerebral cortex and hippocampus. GSK-3β (Glycogen Synthase Kinase-3β) is regarded as the most important and promising target for therapeutic use because GSK-3β expression levels increase with age and are the most abundant and hyperactive in the brains of patients with AD. GSK-3β activation or upregulation can contribute to neurodegeneration by promoting amyloid beta (Aβ) production and tau hyperphosphorylation. Whereas the underlying mechanism for abnormal production of GSK-3β in AD brains remains unclear.</p><p><strong>Methods: </strong>Maestro was used, which is Schrodinger, for our computational simulation studies. In the present work, different modules that were used in previous studies with a little modification, the modules such as Protein Preparation with the help of Protein Preparation Wizard, Ligand Preparation with the help of LigPrep, for ADME (Absorption, Distribution, Metabolism and Excretion) prediction Qikprop was used, for docking studies Glide module was used, Binding energy prediction the Prime was used and Molecular dynamic simulation (MDs) studies done using Desmond.</p><p><strong>Results: </strong>Our focus is mainly on an <i>in-silico</i> approach, focusing on library generation; first draw an IMID2 (imidazo [1,5-a]pyridine-3-carboxamide) scaffold structure at Enamine and subjected it to a substructure search to target the receptor grid region (ATP-competitive site) of 6Y9R. They were then subjected to various screening processes. Finally, nine compounds were subjected to MDs studies.</p><p><strong>Conclusions: </strong>Nine compounds showed good results with the most stable interactions. Among all the MD studies, the compound (Z3336252116) has shown good interaction and a good docking score. Further experiments and studies are required to confirm these results.</p>\",\"PeriodicalId\":12260,\"journal\":{\"name\":\"F1000Research\",\"volume\":\"13 \",\"pages\":\"773\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12121352/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"F1000Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12688/f1000research.145391.3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"F1000Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/f1000research.145391.3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

背景:迫切需要发现一种理想有效的治疗阿尔茨海默病的方法。在临床症状出现之前,阿尔茨海默病的主要病理特征是神经原纤维缠结、淀粉样斑块、脑部炎症和遍及大脑皮层和海马的神经元萎缩。GSK-3β(糖原合成酶激酶-3β)被认为是最重要和最有希望的治疗靶点,因为GSK-3β的表达水平随着年龄的增长而增加,并且在阿尔茨海默病患者的大脑中最丰富和活跃。方法:我们使用Maestro,也就是薛定谔,来进行我们的计算模拟研究。在本工作中,我们使用了以前研究中使用的不同模块,并进行了一些修改,例如使用Protein Preparation Wizard进行蛋白质制备,使用LigPrep进行配体制备,使用Qikprop进行ADME(吸收、分布、代谢和排泄)预测,使用Glide模块进行对接研究,使用Prime进行结合能预测,使用Desmond进行分子动力学模拟研究。结果:我们的重点主要是在一个硅片的方法,专注于库的生成;我们首先在Enamine上绘制了咪唑[1,5-a]吡啶-3-羧酰胺(imid2)支架结构,并对其进行了亚结构搜索,以靶向6Y9R的受体网格区域(atp竞争位点)。然后对他们进行各种筛选。最后,我们选择了9个化合物进行分子动力学模拟研究。结论:9个化合物具有良好的相互作用效果,相互作用最稳定。需要进一步的实验和研究来证实这些结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Molecular docking studies and molecular dynamic simulation analysis: To identify novel ATP-competitive inhibition of Glycogen synthase kinase-3β for Alzheimer's disease.

Background: The discovery of an ideal and effective therapy is urgently required for the treatment of Alzheimer's disease (AD). The main pathological hallmarks of Alzheimer's disease that appear before the clinical symptoms are neurofibrillary tangles, amyloid plaques, brain inflammation, and neuronal atrophy throughout the cerebral cortex and hippocampus. GSK-3β (Glycogen Synthase Kinase-3β) is regarded as the most important and promising target for therapeutic use because GSK-3β expression levels increase with age and are the most abundant and hyperactive in the brains of patients with AD. GSK-3β activation or upregulation can contribute to neurodegeneration by promoting amyloid beta (Aβ) production and tau hyperphosphorylation. Whereas the underlying mechanism for abnormal production of GSK-3β in AD brains remains unclear.

Methods: Maestro was used, which is Schrodinger, for our computational simulation studies. In the present work, different modules that were used in previous studies with a little modification, the modules such as Protein Preparation with the help of Protein Preparation Wizard, Ligand Preparation with the help of LigPrep, for ADME (Absorption, Distribution, Metabolism and Excretion) prediction Qikprop was used, for docking studies Glide module was used, Binding energy prediction the Prime was used and Molecular dynamic simulation (MDs) studies done using Desmond.

Results: Our focus is mainly on an in-silico approach, focusing on library generation; first draw an IMID2 (imidazo [1,5-a]pyridine-3-carboxamide) scaffold structure at Enamine and subjected it to a substructure search to target the receptor grid region (ATP-competitive site) of 6Y9R. They were then subjected to various screening processes. Finally, nine compounds were subjected to MDs studies.

Conclusions: Nine compounds showed good results with the most stable interactions. Among all the MD studies, the compound (Z3336252116) has shown good interaction and a good docking score. Further experiments and studies are required to confirm these results.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
F1000Research
F1000Research Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
5.00
自引率
0.00%
发文量
1646
审稿时长
1 weeks
期刊介绍: F1000Research publishes articles and other research outputs reporting basic scientific, scholarly, translational and clinical research across the physical and life sciences, engineering, medicine, social sciences and humanities. F1000Research is a scholarly publication platform set up for the scientific, scholarly and medical research community; each article has at least one author who is a qualified researcher, scholar or clinician actively working in their speciality and who has made a key contribution to the article. Articles must be original (not duplications). All research is suitable irrespective of the perceived level of interest or novelty; we welcome confirmatory and negative results, as well as null studies. F1000Research publishes different type of research, including clinical trials, systematic reviews, software tools, method articles, and many others. Reviews and Opinion articles providing a balanced and comprehensive overview of the latest discoveries in a particular field, or presenting a personal perspective on recent developments, are also welcome. See the full list of article types we accept for more information.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信